학술논문
Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2
Document Type
article
Author
Joanne Reekie; Henrik Stovring; Henrik Nielsen; Isik S. Johansen; Thomas Benfield; Lothar Wiese; Nina Breinholt Stærke; Kasper Iversen; Ahmed Basim Mustafa; Kristine Toft Petersen; Maria Ruwald Juhl; Lene Surland Knudsen; Mette Brouw Iversen; Sidsel Dahl Andersen; Fredrikke Dam Larsen; Eva Anna Marianne Baerends; Susan Olaf Lindvig; Line Dahlerup Rasmussen; Lone Wulff Madsen; Wendy Bannister; Tomas Oestergaard Jensen; Lisa Loksø Dietz; Sisse Rye Ostrowski; Lars Østergaard; Martin Tolstrup; Jens D. Lundgren; Ole Schmeltz Søgaard
Source
International Journal of Infectious Diseases, Vol 146, Iss , Pp 107111- (2024)
Subject
Language
English
ISSN
1201-9712
Abstract
Objectives: This study aimed to compare antibody trajectories among individuals with SARS-CoV-2 hybrid and vaccine-induced immunity. Methods: Danish adults receiving three doses of BTN162b2 or mRNA-1237 were included prior to first vaccination (Day 0). SARS-CoV-2 anti-spike IgG levels were assessed before each vaccine dose, at Day 90, Day 180, 28 days after 3rd vaccination (Day 251), Day 365, and prior to 4th vaccination (Day 535). SARS-CoV-2 PCR results were extracted from the national microbiology database. Mixed-effect multivariable linear regression investigated the impact of hybrid-immunity (stratified into 4 groups: no hybrid immunity, PCR+ prior to 3rd dose, PCR+ after 3rd dose and before Day 365, PCR+ after Day 365) on anti-spike IgG trajectories. Results: A total of 4,936 individuals were included, 47% developed hybrid-immunity. Anti-spike IgG increases were observed in all groups at Day 251, with the highest levels in those PCR+ prior to 3rd dose (Geometric Mean; 535,647AU/mL vs. 374,665AU/mL with no hybrid-immunity, P